Experimental drug daraxonrasib doubles survival time in advanced pancreatic cancer trial
A Phase 3 clinical trial revealed that patients with advanced pancreatic cancer lived an average of 13.2 months on daraxonrasib, compared to 6.7 months on traditional chemotherapy.
pexels